Ascendiant analyst Edward Woo raised the firm’s price target on Lucid Diagnostics (LUCD) to $8.25 from $8 and keeps a Buy rating on the shares following the company’s Q3 report issued on November 12. Expected high growth and Medicare coverage in 2026 should drive the stock “much higher,” the analyst contends.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics’ esophageal precancer detection tools show efficacy in study
- Lucid Diagnostics files $175M mixed securities shelf
- Lucid Diagnostics: Buy Rating Backed by Strong Growth, Financial Stability, and Strategic Expansion
- Lucid Diagnostics: Positive Indicators and Medicare Reimbursement Potential Support Buy Rating
- Positive Outlook for Lucid Diagnostics: Buy Rating Affirmed Amid Growth in EsoGuard Test Volumes and Strong Financial Management